EndoQuest Robotics Secures Series D-2 Funding Round co-led by Crescent Enterprises and Dr. Fred Moll (GlobeNewswire)

EndoQuest Robotics just secured a Series D-2 funding round co-led by Crescent Enterprises and surgical robotics pioneer Dr. Fred Moll—aiming to fast-track its flexible endoluminal surgical platform through FDA clearance and pivotal trials. Backed by investors like UTHealth Houston and Puma Venture Capital, EndoQuest is advancing the PARADIGM study in top hospitals (Mayo, Cleveland Clinic, Brigham, and more), showcasing its potential to remove complex colorectal lesions without invasive surgery. With bold ambitions in GI procedures, cutting-edge visualization tech, and a growing U.S.–Korea presence, the company is positioning itself as a category-defining force in scar-free robotic surgery.